MARKET WIRETradingView • 10h ago
YD Bio Limited Estimates – NASDAQ:YDESTradingView report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.
Why YDES Stock advanced +1.19% Today — RQD Quant Desk Flash
$5.94 +1.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.94
YD Bio Limited (YDES) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $415.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on YDES Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is YDES stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, YD Bio Limited (NASDAQ: YDES) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.94 (+1.19% 1D, market cap $415.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does YDES compare to FLGT and BDSX in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), YDES carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -20.0%. By comparison, FLGT (Fulgent Genetics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -6.8%, cap $596.5M) and BDSX (Biodesix Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M). Among the 5-stock peer group, YDES leads on earnings multiple (N/A) while FLGT leads on capital efficiency (-6.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for YDES?
▼
Per YDES's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011674), YD Bio Limited generated $596.8K in revenue (+16.9% YoY), -$8.3M in net income, and -$8.0M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.94 (+0.02%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-6.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for YDES)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY YDES SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (32% of score)
Altman Z-Score 13.44 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (23% of score)
FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 51.7 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$6.33-3.3% Next Q
52
Q2 (-2Q)Grade D$6.12-13.6% Next Q
49
Q3 (-1Q)Grade D$5.29+12.3% Next Q
47
CurrentGrade D$5.94-6.5% Hist 90D α
44
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a YDES Turnaround Squeeze
While YDES currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.15) and Max Pain ($6.24) forces dealer call-delta covering toward $16.51.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $YDES• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “YDES Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why YDES Stock advanced +1.19% Today — RQD Quant Desk Flash
YD Bio Limited (YDES) advanced +1.19% to $5.94, trading at 30% of its 52-week range ($1.7 – $15.72). Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 30% of its 52-week range ($1.7 – $15.72) with RSI-14 at 51.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.94 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: YDES Posts 96/100 Macro Tailwind Score as Net Liquidity Elasticity Hits 6.00x Beta
Live YDES Headlines & Catalysts
RISK WATCHStock Titan • 13h ago
A no-blood-draw questionnaire brings cancer risk assessment to a workplace wellness appStock Titan report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.
RISK WATCHInvesting.com India • 16h ago
YD Bio launches $10 AI cancer risk assessment tool By Investing.comInvesting.com India report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.siam.in/ • 19h ago
YD (YDES) Gains +1.39% — Support Holds at $5.56 2026-10-22 - Backspread Tradehttps://www.siam.in/ report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Aspen Neuroscience (ASPE) Stock Price, News & AnalysisStock Titan report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 11d ago
12 Health Care Stocks Moving In Thursday's Intraday SessionGainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market cap
MARKET WIREYahoo • 13d ago
YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness ProgramsTAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring YDES)
- ✓Walkthrough of YDES's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
YDES // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.33%▲ ASCENDING CHANNEL
2026-11-02O $6.28H $6.28L $5.87C $5.94VOL 96.2K
RES: $9.05SUP: $2.77SMA50: $5.15SMA200: $5.50
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
YDES Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +16.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on YDES today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for YDES. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for YDES today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (YDES)
Health Care Rank #439 of 1016
⚔️ FLGT vs YDES Full Matrix →
1. Head-to-Head Health Care Peer Comparison (YDES vs. FLGT, BDSX, TLSI, XGN)
Industry: Medical Specialities (41 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, YD Bio Limited (YDES) ranks #439 by composite RQD confidence (44/100, grade D) and #477 by equity capitalization ($415.8M). Within this direct 5-issuer industry benchmark cohort, YDES leads on earnings valuation at N/A trailing P/E, while FLGT leads on capital efficiency and profitability with -6.8% ROIC and 40.6% gross margin. YDES currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| YDES
ACTIVE
YD Bio Limited | D | 44/100 | — | 28.1% | -20.0% | +1.19% | $415.8M | Benchmark Subject |
| FLGT Fulgent Genetics Inc. | D- | 35/100 | — | 40.6% | -6.8% | -4.89% | $596.5M | /flgt-vs-ydes → |
| BDSX Biodesix Inc. | D- | 42/100 | — | — | -35.0% | -5.93% | $260.8M | /bdsx-vs-ydes → |
| TLSI TriSalus Life Sciences Inc. | E | 31/100 | — | 84.6% | -35.0% | -4.14% | $237.7M | /tlsi-vs-ydes → |
| XGN Exagen Inc. | D- | 36/100 | — | 58.3% | -35.0% | -1.26% | $210.8M | /xgn-vs-ydes → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002011674In its most recent audited fiscal period (FY2025, filed 2025-12-31), YD Bio Limited (YDES) reported GAAP revenue of $596.8K (+16.9% vs. FY2024 revenue of $510.4K , and +70.5% cumulative change since FY2023) , GAAP net income of -$8.3M, operating cash flow of -$6.6M, and free cash flow of -$8.0M (-519.4% YoY). On the balance sheet, YDES closed FY2025 with $13.8M in total assets against $0 in total debt (Altman Z-Score: 13.44, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $596.8K | -$8.3M | -$6.6M | -$8.0M | $13.8M | — |
| FY2024 (FY) | 2024-12-31 | $510.4K | -$1.4M | -$1.2M | -$1.3M | $6.9M | — |
| FY2023 (FY) | 2023-12-31 | $350.1K | $13.6K | -$55.7K | -$55.7K | — | — |
3. YDES Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs YDES stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, YD Bio Limited (NASDAQ: YDES) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.94 (+1.19% 1D, market cap $415.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
How does YDES compare to FLGT and BDSX in the Health Care sector?
Within the Health Care sector (Medical Specialities), YDES carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -20.0%. By comparison, FLGT (Fulgent Genetics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -6.8%, cap $596.5M) and BDSX (Biodesix Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M). Among the 5-stock peer group, YDES leads on earnings multiple (N/A) while FLGT leads on capital efficiency (-6.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for YDES?
Per YDES's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011674), YD Bio Limited generated $596.8K in revenue (+16.9% YoY), -$8.3M in net income, and -$8.0M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is YDES trading relative to its 50-day, 200-day, and 52-week technical levels?
YDES last traded at $5.94 (+1.19% on volume of 47,357 shares), positioning the stock +15.34% above its 50-day simple moving average ($5.15) and +8.00% above its 200-day simple moving average ($5.50). Across its 52-week range of $1.70 to $15.72, YDES sits at the 30.2% percentile with a 14-day RSI of 51.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.20 to $6.68).
YDES Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is YDES stock moving today?
Why YDES Stock advanced +1.19% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 44/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
YDES — YD Bio Limited: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:36:49Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, YDES scores 44 out of 100, a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8 / 20 (ROIC -20%; FCF yield -1.93%); Whale 13F Flow at 9 / 20 (institutional accumulation and options positioning); Insider Conviction at 3 / 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 10 / 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 14 / 20 (Altman Z 13.44; Piotroski F 4/9; Debt/Equity 0.5). The weakest pillar is insider conviction, and the cash engine is also weak given negative ROIC and negative free-cash-flow yield. The forensic balance sheet is the strongest pillar, with a high Altman Z-Score and a low Debt/Equity ratio, though the Piotroski F-Score of 4/9 is mid-range rather than strong. For a prospective investor, the practical implication is that the rating weighs current cash generation and insider signals heavily against the stock; the balance-sheet strength provides some cushion, but the cash-flow and insider pillars are the primary reasons for the underperform label.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.6M | $-5.3M | $-8.3M | N/A | $-8.0M | $6.0M | N/A |
| FY 2024 | $0.5M | $-1.5M | $-1.4M | N/A | $-1.3M | $3.1M | N/A |
| FY 2023 | $0.4M | $-0.0M | $0.0M | N/A | $-0.1M | N/A | N/A |
Per the SEC financials, losses widened from FY 2023 to FY 2025 while revenue grew modestly, from $0.4M to $0.6M. The gross margin is 28.1% per the market data, but operating and net margins are both -60%, and ROIC is -20%. Per the Roarable RQD rating, the Altman Z-Score is 13.44 and the Piotroski F-Score is 4/9, with a Debt/Equity ratio of 0.5. Cash rose to $6.0M in FY 2025 from $3.1M in FY 2024, but free cash flow was $-8.0M, so the cash balance reflects financing or other inflows that the source data does not detail.
Recent Catalysts & News Wire Analysis
Per the recent news wire, the items are: a TradingView market report (market wire, yellow); a Stock Titan item on a no-blood-draw cancer risk questionnaire for a workplace wellness app (risk watch, red); an Investing.com India item on a $10 AI cancer risk assessment tool (risk watch, red); two price-action items noting support at $5.56 (catalyst, green); and a Stock Titan page on a different company, Aspen Neuroscience (ASPE), tagged to YDES (market wire, yellow). The price-action items are technical commentary rather than fundamental events. Per the Butterfly Supply-Chain Graph, the proprietary signal is a LIQUIDITY_TAILWIND labeled "MACRO TAILWIND SCORE (96/100)," direction BULLISH, severity 94. The associated brief cites a Net Liquidity Elasticity of 6.00x and notes True Net Liquidity contracted -0.64% over four weeks to $5,746B. This is a macro-level signal; the source data does not link it to company-specific fundamentals.
Open Questions
- What are the trailing EPS and P/E figures, given that EPS is N/A across all reported periods?
- What is the debt position, given that debt is N/A in every reported period while Debt/Equity is listed as 0.5?
- What drove the rise in cash from $3.1M to $6.0M in FY 2025 while free cash flow was negative?
- Which specific insider and institutional transactions underlie the insider and whale pillar scores?
- Does the AI cancer risk assessment product generate reported revenue, and at what scale?
YDES Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for YD Bio Limited (YDES) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 10h ago
YD Bio Limited Estimates – NASDAQ:YDES TradingView report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 13h ago
A no-blood-draw questionnaire brings cancer risk assessment to a workplace wellness app Stock Titan report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Investing.com India • 16h ago
YD Bio launches $10 AI cancer risk assessment tool By Investing.com Investing.com India report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 19h ago
YD (YDES) Gains +1.39% — Support Holds at $5.56 2026-10-22 - Backspread Trade https://www.siam.in/ report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Aspen Neuroscience (ASPE) Stock Price, News & Analysis Stock Titan report covering YD Bio Limited (YDES) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 11d ago
12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market cap
🟡 MARKET WIRE Yahoo • 13d ago
YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
YDES Bull vs. Bear Conversation Board — What's Your Call at $5.94?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON YDES 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $5.17 (-11.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is YDES (D • RQD 44/100) a Buy at $5.87?
Welcome to the YDES (YD Bio Limited) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $4.46 (-24.0%)
Spot @ $5.87 Pump the brakes on YDES — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on YDES, but look at what you are paying: current EV/EBITDA multiples with 28.1% gross margins. Unless YD Bio Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $7.16 (+22.0%)
Spot @ $5.87 YDES cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on YDES, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $5.87 (52-wk range $1.70 - $15.72), any beat on forward guidance forces shorts and underweight funds to chase.